G-treeBNT Co., Ltd. completed the acquisition of YS Pharm Co., Ltd.
September 03, 2018
Share
G-treeBNT Co., Ltd. (KOSDAQ:A115450) agreed to acquire YS Pharm Co., Ltd. for KRW 6.7 billion on June 29, 2018. The scheduled merger contract signing date is July 4, 2018. On July 4, 2018, the parties signed the merger contract. Under the terms of the deal, G-treeBNT Co., Ltd. will issue 2.372299137 shares for every 1 share of YS Pharm Co., Ltd. For the year ending December 31, 2017, YS Pharm Co., Ltd. reported total assets of KRW 13.7 billion, total capital of KRW 1.4 billion, sales of KRW 34.9 billion and net profit of KRW 461.8 million. The deal is subject to approval of Board of Directors of G-treeBNT Co., Ltd. The Board of Directors of G-treeBNT Co., Ltd. passed a resolution for the deal on June 29, 2018. The deal was approved by the Board of Directors of G-treeBNT Co., Ltd. and YS PHARM CO., LTD. on August 1, 2018. The scheduled merger date is September 4, 2018. KRW Ghilin Accounting Corporation acted as external rating institution in the deal.
G-treeBNT Co., Ltd. (KOSDAQ:A115450) completed the acquisition of YS Pharm Co., Ltd. on September 4, 2018.
HLB Therapeutics Co Ltd, formerly G-treeBNT Co Ltd, is a Korea-based company engaged in the research and development of optimized multimedia software for various digital appliances including cellular phones. Along with its affiliates, the Company operates solution business segment, which provides embedded graphic user interface (GUI) software solutions as well as wired and wireless integration multimedia platform solutions. Its embedded GUI products include FXUI-two-dimensional (2D), FXUI-three-dimensional (3D) and FX Studio, which are used for cellular phones and embedded equipment. Its wired and wireless integration multimedia platform products include FX-Flash and others, which are used for cellular phones and other mobile devices; electronic components manufacturing business segment, which provides transformers, pumps, motors and others, as well as educational and bio pharmaceutical business segments.